更新于：2024-11-01

Iron deficiency anemia of pregnancy

孕期缺铁性贫血

更新于：2024-11-01

基本信息

别名

Iron def anaemia of pregnancy、Iron def anemia of pregnancy、Iron deficiency anaemia of pregnancy

+ [2]

简介-

关联

项与孕期缺铁性贫血相关的药物

Ferumoxytol

非莫妥尔

靶点-

作用机制

铁替代物

在研机构

东南大学 [+3]

原研机构

AMAG Pharmaceuticals, Inc.

在研适应症

伴随慢性肾病的贫血 [+3]

非在研适应症

脑癌 [+5]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2009-06-30

Ferrous bisglycinate

甘氨酸亚铁

靶点-

作用机制-

在研机构-

原研机构-

在研适应症-

非在研适应症

腹痛 [+13]

最高研发阶段无进展

首次获批国家/地区-

首次获批日期1800-01-20

项与孕期缺铁性贫血相关的临床试验

NCT06425796 / Not yet recruitingN/AIIT

Impact of Maternal Adiposity on Maternal Iron Status and Requirements: a Randomised Intervention Study

This study aims to explore how body fat influences the response to either 25 or 50 mg of daily iron supplements during pregnancy. We will conduct a double-blind randomized controlled intervention study involving 312 pregnant women recruited from antenatal clinics in the Northern Trust Area. Participants will be randomly assigned to receive either 25 or 50 mg of iron per day from 12 weeks of pregnancy until delivery, using the Active Iron supplement brand. Blood samples will be collected at 12, 28 and 36 weeks gestation and umbilical cord blood will be collected at delivery. Anthropometric measurements will be taken at each visit, and participants will complete questionnaires on various aspects of health and lifestyle, mental health, gastrointestinal symptoms, and compliance.

开始日期2024-05-20

申办/合作机构

University of Ulster

[+1]

ISRCTN16425597 / Recruiting临床3期IIT

A Phase III, multi-centre, randomized placebo-controlled trial of oral iron supplementation for the prevention of maternal anaemia

开始日期2024-03-01

申办/合作机构

NHS Blood & Transplant

ChiCTR2300079227 / SuspendedN/AIIT

A clinical study on the effect of vitamins (A, D, E) on iron metabolism in pregnant women with iron deficiency anemia

开始日期2024-01-01

申办/合作机构-

100 项与孕期缺铁性贫血相关的临床结果

登录后查看更多信息

100 项与孕期缺铁性贫血相关的转化医学

登录后查看更多信息

0 项与孕期缺铁性贫血相关的专利（医药）

登录后查看更多信息

项与孕期缺铁性贫血相关的文献（医药）

2024-06-01·European Journal of Obstetrics & Gynecology and Reproductive Biology

How does maternal anemia affect the levels of umbilical cord brain-derived neurotrophic factor?

Article

作者: Akkaya Fırat, Asuman ; Mungan Akın, İlke ; Özel, Ayşegül ; İpek Aytok, Gökçe

OBJECTIVEIn this study, we aimed to evaluate the effect of maternal iron deficiency anemia on the umbilical cord level of brain-derived neurotrophic factor (BDNF), which plays a very important role in the central nervous system.METHODSOur research was planned as a quantitative, prospective, and analytical type of study. A total of 90 volunteers, term, singleton pregnant hospitalized in the Health Sciences University Ümraniye Training and Research Hospital Gynecology and Obstetrics Clinic between September 2021 and August 2022 were included in this study. While 45 of these pregnants were pregnant women with iron deficiency anemia (hemoglobin ≤ 110 g/L and serum ferritin level ≤ 12 μg/L), 45 cases were in the control group without iron deficiency anemia (hemoglobin > 110 g/L, serum ferritin > 12 μg/L). When pregnant were admitted to the hospital, blood samples were taken to analyze hemoglobin, mean cell volume (MCV), iron, unsaturated iron binding capacity, total iron binding capacity, serum ferritin, transferrin, and CRP levels. Also, we noted the maternal age, gravida, parity, birth weight, head circumference, type of birth, 1. minute Apgar score, and 5. minute Apgar score. During the delivery; after the umbilical cord had been clamped and cut, we took 5 cc of umbilical cord blood. Then, we put it in the serum-separating laboratory tubes. After we centrifuged these blood samples, we put the serum parts in the Eppendorf tubes to be stored at -80 degrees Celsius. At the end of the study, we calculated the level of BDNF using special human brain-derived neurotrophic factor ELISA kits. The umbilical cord BDNF levels of the maternal iron deficiency anemia group and the control group were compared statistically.RESULTSWhen we evaluated the fetal umbilical cord BDNF values of 90 participants, the median value BDNF in the babies of 45 anemic mothers was 3.16 (IQR 0.73), and the median BDNF value of the babies of 45 healthy mothers was 5.37 (IQR 1.02). We found a statistical difference between BDNF and hemoglobin, hematocrit, MCV, and iron values between these two groups.CONCLUSIONIn conclusion, the BDNF value of the babies of healthy individuals is higher than that of anemic individuals. Our study showed that the amount of BDNF in the umbilical cord blood was significantly affected by maternal iron deficiency anemia.

2024-05-13·Cureus

Efficacy of Intravenous Iron Infusion in Gestational Iron Deficiency Anemia in Dubai, United Arab Emirates, During 2018–2019: A Retrospective Study

Article

作者: Kausar, Shabana ; Alfalasi, Hamda A

OBJECTIVEThe objective is to investigate the effectiveness of intravenous (IV) iron infusion in increasing hemoglobin levels in gestational iron deficiency anemia (GIDA) patients in a tertiary-care hospital in Dubai emirate, United Arab Emirates (UAE).METHODSThis is a retrospective cohort study of GIDA patients who were exposed to IV iron infusion supplementation. Study data of 40 cases aged 25-45 in a tertiary-care hospital in the UAE between 2018 and 2019 were analyzed. Variables accounted for were maternal age, age of gestation when IV iron was administered, and IV iron dose.RESULTSThe average hemoglobin level before the intervention was 9 g/dL, and the average change after the intervention was 10.4 g/dL with a mean of 1.4 g/dL difference between before and after the intervention.CONCLUSIONSupplementation of IV iron infusion in GIDA patients was seen to have increased the hemoglobin level after the intervention; however, the increase did not meet the recommended range of 12-16 g/dL.

2024-03-06·The American Journal of Tropical Medicine and Hygiene

Association between Iron–Folic Acid Supplementation during Pregnancy and Maternal and Infant Anemia in West Java, Indonesia: A Mixed-Method Prospective Cohort Study

Article

作者: Wirawan, Fadila ; Sartika, Ratu Ayu Dewi ; Mohd Shukri, Nurul Husna ; Putri, Primasti Nuryandari

ABSTRACT.The Indonesian government has provided iron–folic acid (IFA) supplementation in response to maternal pregnancy iron-deficiency anemia. However, community-based cohorts on IFA’s effects on maternal and infant anemia are limited. A mixed-method study design with a primary longitudinal cohort was used to observe the association between IFA and anemia in mothers and infants. Iron–folic acid supplementation was observed throughout pregnancy. Anemia status was based on a single hemoglobin assessment using HemoCue Hb 201 + in the second or third trimester of pregnancy for the mother and at birth for the infant. Qualitative data were collected via in-depth interviews (IDIs) and a forum group discussion (FGD). Iron–folic acid supplementation with > 180 tablets throughout pregnancy was associated with lower pregnancy anemia (adjusted relative risk [aRR] = 0.25, 95% CI: 0.092–0.664, P = 0.006) after adjusting for potential confounding variables. Supplementation with IFA was not associated with infant anemia (RR = 1.033, 95% CI: 0.70–1.54, P = 0.873 for 90–180 tablets and RR = 1.07, 95% CI 0.70–1.63, P = 0.774 for > 180 tablets). The IDIs and FGD suggested that IFA and multivitamin content knowledge, IFA consumption monitoring, and paternal involvement were important in IFA supplementation and effectiveness in reducing anemia. Iron–folic acid supplementation was associated with reduced maternal but not infant anemia. Because maternal anemia is associated with infant anemia, an anemia monitoring program for women in early pregnancy is vital in addressing infant health. Paternal involvement was also identified as a major factor in maternal and child health.